t2biosystems 产品代理
t2biosystems 产品代理
脓毒症每年夺去的生命比乳腺癌、前列腺癌和艾滋病的总和还要多。我们专注于通过开发工具，以比以往更快的速度识别最常见和最致命的败血症病原体，从而消除败血症导致的死亡。速度在脓毒症管理中至关重要。患者接受有效治疗的速度越快，他们就越有可能存活并获得更好的结果。更好的是，针对血流感染的早期靶向治疗可以完全阻止败血症的进展。
T2Bacteria Panel
T2Candida Panel
T2Resistance Panel
T2Dx Instrument
T2MR Technology
At T2 Biosystems, our mission is to save lives and improve healthcare by empowering clinicians to get patients on the right therapy faster. We come to work every day to solve critical needs in healthcare diagnostics with innovative solutions built on our game-changing T2 Magnetic Resonance (T2MR®) detection technology.
Sepsis claims more lives annually than breast cancer, prostate cancer, and AIDS combined. We’re focused on eradicating deaths due to sepsis by developing tools that help identify the most common and deadly sepsis-causing pathogens faster than ever before. Speed is critical in sepsis management. The faster patients receive effective treatment, the more likely they are to survive and have better outcomes. Better yet, early targeted therapy for bloodstream infections may prevent the progression to sepsis altogether.
Our blood tests provide actionable results in just 3 to 5 hours. The only other way to identify the species-specific diagnosis requires a blood culture, which can take 1 to 5 days or more. Today, T2Direct Diagnostics™ are getting patients on the right therapy faster, and the expedited identification of negative test results allows rapid de-escalation of unneeded therapy. In partnership with hospitals around the world, T2 Biosystems technology is uniquely positioned to strike a huge blow to sepsis and the hundreds of thousands of lives it takes each year.
Our T2Bacteria® and T2Candida® Panels run on the automated T2Dx® Instrument. They are the first and only FDA-cleared and CE-marked blood tests that identify sepsis-causing pathogens without the wait for blood culture. As hospitals continue to adopt our technology, it will represent a paradigm shift that can potentially result in thousands of patients going home to their families instead of the tragic, and potentially avoidable, alternative.
We also have a strong pipeline of products for sepsis management, including bacterial resistance panels and a Lyme disease panel.
